IgAN  EXPLAINED

However, more than half of patients remain above target proteinuria level of >0.75–1g/d and are at high risk of disease progression^1–4

Immunosuppressive drugs should be considered only in patients with IgAN who remain at high risk of progression despite maximal supportive care. In patients where immunosuppression is being considered, a detailed discussion of the risks and benefits of each drug should be undertaken with the patient recognizing that adverse treatment effects are more likely in patients with a reduced eGFR¹